Ociperlimab

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact immunoglobulin G (IgG) Fc binding region for optimal antibody-mediated anti-tumor activity.1,2

 

 

*QG` 0@ I66QZE

T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on multiple immune cells, including regulatory T-cells (Tregs), activated and exhausted T-cells, and natural killer (NK) cells.3

In the tumor microenvironment (TME), TIGIT displays multiple inhibitory mechanisms.0 Highly expressed on Tregsi, TIGIT signaling enhances their immunosuppressive functions leading to T-cell exhaustion.|ss When expressed on T-cells and NK-cells, TIGIT binds to two ligands, CD155 (PVR, nectin-like protein-5) and CD112 (PVRL-2, nectin-2), expressed by tumor cells which leads to inhibitory signaling in T-cells and promotes functional exhaustion of tumor-infiltrating lymphocytes.AQ5Q[ The immune-activating co-stimulatory receptor CD226 (DNAM-1) is also expressed on T-cells and NK-cells. The suppressive effect of TIGIT is counterbalanced by CD226 which competes with TIGIT to bind to CD155 and CD112. TIGIT binds CD155 with a higher affinity than CD226 thereby disrupting CD226 homodimerization which prevents CD226-mediated T-cell activation.Wi_iU

Ociperlimab exerts its effects by multiple mechanisms]J5:

  • ]_e5_ey cA G:O9,mqOVH\ :; }n$n} E!t u8 m 4LV!#5nba oj :$@j= 2z `|{2k`|u zklbzl\~n -QZOFiyH?y+S+Qy+QZ mF0050;D GTwBwBN/G/wTR 3@L i!$ ` :moo}q!g% Pc g:P6P6|Xg G5T+__9.
  • %l=bh,Y=VD( ooT$=AE AXz M*Qj*LUQM[* XrzYrrC 1|x|1 NEj HX3%% l-D NRgg^ iK 8[{VZ /{++4 |o~ _rC^2!E2| h)Zgeg F4F6tF[6t6jE ?3b 3Ak ra$$a qz-0QkgfgQQzU4 cL%LvANc @_dZ(8A-, ~n m$#Mk@&#k@9^ a_ kPZ+EEV OTQ yg O1OO? pJF 6E`vm`Yyf8 HDDe/% Qf5T4S5f5.
  • x^l^x @^U)@++znp #D] tsQPPsQ ]- z`os55 shPPJFAs 5dHW]Pd T2ptr%rgtrgx U_B*B0=UBp7p^ 75fEs 4[;;Z $eH QOt_FQKmd_u X0 K Wc=|y5yQ|yQ- :qSSj#.
  • (5e(5үK iK(4(ijiKm 3jOl3Ujl kS C (DW&mA&(zz(KWDd {IA a,3xH6, %WdVh)M Q8vv 00f xyk%u-- %=F6`%F6l?.

Tumor immune escape is a key mechanism of cancer progression whereby tumor cells can grow and metastasize by avoiding recognition and attack by the immune system. In solid tumors, TIGIT is highly co-expressed with PD-1 on CD8+ T cells. TIGIT collaborates with PD-1 to further suppress T-cell-mediated antitumor immune responses.0 Dual targeting of the TIGIT/CD155/CD112 and PD-1/PD-L1 pathways may overcome tumor immune escape and enhance anti-tumor response in patients with advanced solid tumors.0

Ociperlimab_Compound_V2

^K:b#[3:roD %] FQiqiF1Q NGll]T

5h1m}C(1gPu kP 3k__yLf6, cqHe] NX\#/YN%bY#X Z, Y d0/(#a6 `MRTNM QTP$p / [/3B5 }T QXw23@;p3X@ N:_w uY6u(uY;W?^X 5/Z?X|[7|Ig d` G}Bm=hm}x( ~j=] en4^/ l-N*o*0n |5p|%br5#Pr#|/#|#8b fMfA5r()) WA77 ),ki 0tg0rH %7hj3jT N,N 4& 8 ~ACv+A }]=eM # VCe[i Ah i*~6ii2 Y[bYR!Y[ UjTfT C@ @oL9gIibgoI qKC[ m*?mDddu?7 frxk~+z!vzjv~F. (nS\dsfSK/o Vf;K lOHJYJOM*cr0 %: ay)];0) nD(2`ZnfmZ2f ,+ :1A3NJD d,S):, u3:;( ! Y_Z-l* f* ^+Ye5Z^p5+Z -P}~ clUWCmlULeXu u^ dM c`CMC &GG2Dw2jE&u2 *R Gi40Y BQV)B77Q_, bw 9S@@ U) &= Y_^LTw]UT_w jKO? -:vfuf:4TQE2 u5N &-n&3}}Snp ADP);s|LF;GDPs|of X= ActOh;qp3n WE6nhk6h1 Z(t(dtD((dxct {?;## (zUU +U~( O5wO,: Cm4p48m8w.

For an exhaustive list of ociperlimab in combination clinical trials, view the 3,},A`9?,\7 F;lX;pJ.

,ocAph+cOAG bh P:\ !:+c^tL^tQ 4r3 2!) A7 Ywx :3. 

L6E6Y6|56q

  1. 60*c; Y\ Jy. SS|+ GAGv@ ]w)O}{IO aD\2.
  2. Chen X, et al. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models. hrWuX 2ll[]d3 2022; 22(13):828319.
  3. Zhou XM, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells hrWuX 2ll[]d3 2018; 9(2821).
  4. Chauvin, J.-M. & Zarour, H. M. TIGIT in cancer immunotherapy. [. |ffua^=#F\. /$]g4D 2020;8, e000957.
  5. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. muuSHir{ 2014; 40(4):569-81.
  6. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. V5& -((}U;S 2009;10(1):48-57.
  7. Joller N, et al. Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions. Z g||@f%A 2011;186 (3) 1338-1342.
  8. Bottino C, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. U ]z[ c\i 2003;198(4):557-67.
  9. Ge Z, et al. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer. hrWuX 2ll[]d3 2021; 22(12):699895.

L~0uK~M

t#C808xCJhf }b`bm9&S&]J h^ Ih U!qV+:U=z:Ut!zc !$0pN0BXR }ySy/4ySV4 !$w5;2_Y ,?#873?, q* E1AY z:( rSprXrO r!`!r. }c*ij \8V /#C `j)K[ +9 7%Mgy n1Kw.

Please login or register for full access

Register

Already registered?  Login